https://www.selleckchem.com/pr....oducts/zilurgisertib
To investigate the relationships between various clinical variables and the metformin-induced accumulation of fluorodeoxyglucose (FDG) in the intestine, with distinction between the intestinal wall and lumen, in individuals with type 2 diabetes who were receiving metformin treatment and underwent F-labelled FDG ([ F]FDG) positron emission tomography (PET)-MRI. We evaluated intestinal accumulation of [ F]FDG with both subjective (a five-point visual scale determined by two experienced radiologists) and objective analyses (